Publications by authors named "Itsumi Mizukawa"
Bullous pemphigoid (BP) is an autoimmune subepidermal blistering disease with a linear deposit of autoantibodies at the epidermal basement membrane zone. It was reported that diabetes patients who took a dipeptidyl peptidase-4 inhibitor (DPP4i), an oral antidiabetic drug, had an increased incidence of BP. However, data on DPP4i-related BP are limited.
View Article and Find Full Text PDFAtopic dermatitis (AD) places a burden on work productivity. Recently, dupilumab was approved for AD, but its impact on work productivity in Japanese patients has not been reported. Furthermore, data on the effect of long-term treatment with dupilumab on work productivity are limited.
View Article and Find Full Text PDFArticle Synopsis
- Researchers found that a mutation in the IL36RN gene may play a role in generalized pustular psoriasis (GPP), particularly the c.245C>T (p.Pro82Leu) variant, identified in a patient with adult-onset GPP.
- Although this variant was not present in other psoriasis groups, suggesting a potential link to inflammation, predictions about its pathogenicity have indicated it as benign.
- Further analysis of the patient showed normal expression of IL-36Ra in skin cells, leading to the conclusion that this variant likely does not contribute to the development of GPP.
Article Synopsis
- Apremilast is a drug that specifically inhibits the enzyme phosphodiesterase 4, showing promise in treating psoriasis, but its detailed effects in living organisms needed further investigation.
- The study involved inducing psoriasis-like symptoms in mice using a substance called imiquimod and treating them with apremilast to assess its effects.
- Results indicated that apremilast significantly reduced symptoms by lowering certain inflammatory cells and cytokine levels while promoting regulatory immune cells, suggesting it may effectively treat psoriasis by modulating the immune response.